Conferences

Reports from medical professional meetings related to melanoma.

Melanoma

Eye Tracking and Gating System for Proton Therapy of Uveal Melanomas Presenting Author/Institution: Dongho Shin, Proton Therapy Center, National Cancer Center, Korea Background Ocular melanoma is an uncommon malignancy, usually occurring in the uvea of the eye. For asymptomatic patients and small tumors (<10 mm in diameter and <2 mm in height), observation is often an acceptable treatment. For
Interferon Therapy Delays Disease Recurrence and Prolongs Survival in Patients with Resected Melanoma Jean-Jacques Grob, MD, professor dermatology, University of Marseille, Hopital Sante-Marguerite (Marseille, France), presented a study of interferon alfa-2a as adjuvant therapy in patients with resected (surgically removed) early stage melanoma. Melanoma is a cancer which arises in the pigment cells of the skin, mucuous membranes, eyes and
Cancer Vaccine Triggers Immune System to Recognize Melanoma Unlike vaccines that are used to prevent infectious disease, cancer vaccines attempt to stimulate the body's own immune system to recognize cancer cells as foreign and destroy them. These researchers examined tyrosinase, a normal protein present in melanin (which gives moles their color), and in melanoma cells. Patients were treated with
Melanoma Patients Could be Spared Radical Surgery by Sentinel Node Mapping A technique called "sentinel node mapping" can accurately diagnose the minority of patients whose melanoma has spread, while saving the majority from radical lymph node dissection surgery, according to results of a five-year, multi-center study. In sentinel node mapping, injections of radioisotope makers and blue dye are used to pinpoint the
The 6th World Conference on Melanoma Conference Dates: September 2 - 9, 2005 Conference Location: Vancouver Convention & Exhibition Centre Sponsoring Group: WHO Melanoma Programme Conference Web Page URL: www.worldmelanoma.com Topics Covered: melanoma: surgery, clinical diagnosis, pathology, epidemiology, basic research, dermoscopy, sentinel node biopsy, genetic, vaccine
The Fourth Annual Wallace H. Clark, Jr. Lectureship in Cutaneous Oncology and Melanoma Symposium Conference Dates: Thursday, February 6, 2003 Conference Location: Philadelphia, Pennsylvania Sponsoring Group: University of Pennsylvania Abramson Cancer Center and the Department of Dermatology Topics Covered: Melanoma, cutaneous oncology, and general neoplasia Conference Objectives: To provide updates on melanoma prognosis and issues
First International Melanoma Research Congress Conference Dates: June 21-24, 2003 Conference Location: Wyndham Franklin Plaza Hotel in Philadelphia Sponsoring Group: Foundation for Melanoma Research Conference Web Page URL: www.foundationformelanomaresearch.org Topics Covered: Immunology, Epidemiology, Biology, Molecular Biology and Tumor Microenvironment. Conference Objectives:
The 1st European Conference: Perspectives in Melanoma Management Conference Dates: October 9-11, 2003 Conference Location: Amsterdam, The Netherlands Sponsoring Group: Imedex. Under the auspices of EORTC Conference Web Page URL: www.imedex.com/announcements/emelanoma03.html Topics Covered: EORTC Melanoma Group Program Scientific Reports, Phase III Trials in Stage IV Melanoma, Vaccine Development in
Melanoma Regional Symposium Conference Dates: October 4, 2003 Conference Location: Stabile Research Building at Moffitt Cancer Center, Tampa, Florida Sponsoring Group: Moffitt Cancer Center Conference Web Page URL: www.moffitt.usf.edu Topics Covered: Melanoma, plastic surgery, immune therapy Conference Objectives: Discuss treatment options. Evaluate the latest
The Role Of Sentinel Lymphadenectomy In Thin Cutaneous Melanomas Presenter: Richard J. BleicherPresenter's Affiliation: The John Wayne Cancer Institute, Santa Monica, CAType of Session: ScientificBackground The sentinel lymph node (SLN) biopsy is revolutionizing the surgical management of primary malignant melanoma. Lymphatic mapping and sentinel lymphadenectomy (LM/SL) has become standard to assess regional
Long Term Survival Of Stage II And III Melanoma Patients With Respect To Serial Tyrosinase RT-PCR Testing In Peripheral Blood Presenter: Christiane A VoitPresenter's Affiliation: University of Mainz, Mainz, GermanyType of Session: ScientificBackground Melanoma has a high metastatic potential even in small primary lesions, and an early distinction between localized and regionally/distally advanced disease is of major importance for the patients' treatment and,
Perspectives in Melanoma Conference Dates: September 23-25, 2004 Conference Location: Berlin, Germany Sponsoring Group: Imedex, Inc. Conference Web Page URL: www.imedex.com/calendars/oncology.htm Registration Information: Online at www.imedex.com; Tel: +1 770 751 7332; Fax: +1 770 751 7334; Email: meetings@imedex.com Continuing Education: Yes
Focus on Melanoma Conference Dates: March 31, 2005 Conference Location: University of Pennsylvania Biomedical Research Building II/III, Philadelphia PA Sponsoring Group: The Abramson Cancer Center of the University of Pennsylvania Conference Agenda: 2nd Annual Conference For Patients And Families Whose Lives Have Been Affected By Melanoma Conference
Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients with advanced malignant melanoma Presenter: J.M. KirkwoodPresenter's Affiliation: University of Pittsburgh Cancer InstituteType of Session: ScientificBackground Oblimersen sodium (Genasense, G3139) is an antisense oligonucleotide that selectively targets and specifically binds bcl-2 mRNA resulting in decreased bcl-2 protein translation and increased apoptosis when added to
Canadian Melanoma Conference: Research Frontiers Conference Dates: Thursday, March 2, 2006 to Monday, March 6, 2006 Conference Location: The Fairmont Banff Springs Hotel, Banff, Alberta Sponsoring Group: Alberta Cancer Board Conference Web Page URL: http://www.buksa.com Topics Covered: siRNA guided Approach to Melanoma Treatment Targeted therapy: Sorafenib and ongoing trials
3^rd Annual Focus on Melanoma Date: Friday, May 12, 2006 8:30 AM - 4:30 PM Location: Hilton Hotel, City Line Avenue, Philadelphia, PA Conference Information: Please view the Conference Brochure . Who Should Attend: Patients and families whose lives have been affected by melanoma. Registration: To register, call 215-614-1818 or 1-800-789-PENN (7366) or use the form
8th Annual Wallace H. Clark, Jr., MD Lectureship in Cutaneous Oncology & Melanoma Symposium Conference Dates: Thursday, March 29, 2007 Conference Location: University of Pennsylvania Biomedical Research Building II/III, Ground Floor Auditorium, Curie Blvd., and Osler Way, Phila., PA Sponsoring Group: Penn's Department of Dermatology and the Abramson Cancer Center of the University of Pennsylvania Conference Objectives: After
2007 International Melanoma Congress Conference Dates: November 1-4, 2007 Conference Location: New York Marriott Financial Center, New York, NY Conference Web Page URL: http://www.melanomacongress07.net/main/index.php Topics Covered: Why melanocytes develop into melanoma Why are melanomas so metastatic Why melanomas don't die Wiring of melanoma –
Melanoma 101 Teleconference Conference Dates: Thursday October 18, 2007, 12-1PM Conference Location: Free Teleconference Sponsoring Group: Melanoma Research Foundation Conference Web Page URL: http://www.melanoma.org/Contents.aspx?TeleConfId=218&ContentId=218&Categoryid=99 Topics Covered: Topics to be covered include: Melanoma risk factors What is the optimal
Fourth Annual Focus on Melanoma Conference Dates: May 11, 2007 Conference Location: Hilton Hotel, City Line Avenue, Philadelphia, PA Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania Who Should Attend: Patients and families whose lives have been affected by melanoma. Conference Agenda: Join us for this informative patient and family conference
Sentinel Lymph Node Biopsy Improves Survival Among SEER Patients with Melanoma Presenter: Gimotty P. Presenter's Affiliation: University of Pennsylvania Type of Session: Scientific Background Regional lymph node metastases increase the risk of melanoma-specific death. Sentinel lymph node biopsy (SLNB) provides prognostic information in patients with malignant melanoma (MM); however, its therapeutic role is not well
Proton Therapy of Uveal Melanomas: Thirty years Experience Presenter: Evangelos Gragoudas, MD Affiliation: Massachusetts Eye and Ear Infirmary Introduction Uveal melanoma is a rare malignancy with a rate in the United States of 6 cases per million per year. However, it is the most common intraocular primary malignancy. This tumor is a threat to both the sight and life of the patient. Radiation therapy
Eleventh Annual Wallace H. Clark Jr., MD Lectureship in Cutaneous Oncology Melanoma Symposium Conference Dates: April 29, 2010 Conference Location: University of Pennsylvania, Biomedical Research Building II/III, Ground Floor Auditorium, Curie Blvd. Osler Circle, Philadelphia, PA Sponsoring Group: University of Pennsylvania School of Medicine and Abramson Cancer Center of the University of Pennsylvania Conference Web Page URL:
Proton radiation therapy of ocular melanoma at PSI - long-term clinical exam Presenter: G. Goitein, A. Schalenbourg, J. Verwey, A. Bolsi, C. Ares, L. Chamot, E. Hug, L. ZografosPresenter's Affiliation: Paul Scherrer Institute (PSI) Villigen, Switzerland Type of Session: ScientificBackground There are approximately 2200 cases of eye/orbit malignancies per year. The most common primary intraocular malignancy in
Adjuvant Radiotherapy Improves Regional (Lymph Node Field) Control in Melanoma Patients after Lymphadenectomy: Results of an Intergroup Randomized Trial (TROG 02.01/ANZMTG 01.02) Presenter: B. BurmeisterPresenter's Affiliation: Princess Alexandra Hospital, Brisbane, AustraliaType of Session: PlenaryBackground Approximately 80% of patients with melanoma who undergo lymphadenectomy have high-risk features. Of these high risk patients, approximately 30-50% fail locally following surgical resection. Adjuvant
A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma Presenter: Steven O'Day, The Angeles Clinic and Research Institute, Los Angeles, CA. Background Advanced melanoma (Stage III/IV) has an increasing global incidence. Many patients are diagnosed at a relatively young age, and the disease carries a poor prognosis. Despite multiple trials of experimental therapeutics, there are few good
Twelfth Annual Wallace H. Clark Jr., MD Lectureship in Cutaneous Oncology & Melanoma Symposium Conference Date: April 7, 2011, 8:30 AM - 12:00 PM Conference Location: University of Pennsylvania, Biomedical Research Building II/III, Ground Floor Auditorium, Curie Blvd. Osler Circle, Philadelphia, PA Conference Brochure: PDF Sponsoring Group: Supported, in part, by educational grants from The Noreen O'Neill Foundation for Melanoma
Focus on Melanoma Conference Dates: May 13, 2011, 8am - 3pm Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA Sponsoring Group: Abramson Cancer Center Web Page URL: http://www.penncancer.org/events.cfm?type=1=view%3Devent%26eventid%3D92646431 Topics Covered: HOLD THE DATE The 8th Annual Focus on Melanoma Conference is a full day symposium designed to address
A population-based, case-control study of MC1R variants, ultraviolet light exposure, and melanoma Presenter: D. Polsky Presenter's Institution: New York University Background/Introduction It is well known that ultraviolet light (UV) exposure is associated with increased melanoma risk. In addition, several different genes have been identified as increasing the risk of developing melanoma. Melanocortin-1 receptor gene (MC1R), located
Melanoma as a subsequent neoplasm in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study Presenter: A. S. Pappo Presenter's Institution: St. Jude Children's Research Hospital, Memphis, TN Background Survivors of childhood cancer are at increased risk of developing secondary malignant neoplasms (SMN). Generally speaking, children treated for malignant disease are acknowledged to be at greatly increased risk for SMN following
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma Presenter: P. B. Chapman Presenter's Institution: Memorial Sloan Kettering Cancer Center Background Dacarbazine (DTIC) was approved for melanoma in 1975; the overall response rate has been reported at 7-12% and median OS after starting the drug is less than 8 months. High dose IL-2 was approved in 1998, with a durable CR of 5-7%. IL-2
Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma Presenter: Wolchok Presenter's Affiliation: Memorial Sloan Kettering Cancer Center, New York, NY Background Metastatic melanoma is an aggressive and deadly disease with limited treatment options. The incidence of metastatic melanoma, particularly in young adults, is rising world wide. Typically, the 1-year survival
7th Annual Focus on Melanoma Conference: What’s New in Melanoma and News You Can Use Date/Time: Friday, May 14, 2010, 7:30am – 2:30pm Location: Hilton Hotel 4200 City Avenue Philadelphia, PA Audience: Open to All Sponsor: Cancer - Abramson Cancer Center Cost: This event is free. Registration: This conference is FREE of charge. A $20 donation (non-tax deductible) is suggested to support the